Ose Immunotherapeutics Stock Quote 0RAD - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

4.12

Bid

0.00

Ask

0.00

Volume

0.00 Day's Range 0.00

4.12 52 Week Range 4.12

Market Cap

89.202M

Previous Close

4.12

Open

Last Trade

7.58

(O)

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

138

Shares Outstanding

21,651,000

Dividend Yield

PE Ratio

-7.12

Earnings Per Share (EPS)

-1.06

Revenue

2.23M

Net Profit

-23M

Sector

Coml Physical, Biologcl Resh

Industry

Coml Physical, Biologcl Resh

Website

www.ose-immuno.com

Headquarters

Nantes, Loire-atlantique, Fra

Founded

Ose Immunotherapeutics Sa is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker 0RAD. The last closing price for Ose Immunotherapeutics was 4.12 €. Over the last year, Ose Immunotherapeutics shares have traded in a share price range of 4.12 € to 4.12 €.

Ose Immunotherapeutics currently has 21,651,000 shares outstanding. The market capitalization of Ose Immunotherapeutics is 89.20 € million. Ose Immunotherapeutics has a price to earnings ratio (PE ratio) of -7.12.

OSE Immunotherapeutics présentera les résultats d’induction de Phase 2 de l’anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO

OSE Immunotherapeutics présentera les résultats d’induction de Phase 2 de l’anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO Un abstract clinique sur les...

OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO

OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO A clinical abstract on the induction results from the CoTikiS...

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary...

OSE Immunotherapeutics annonce des avancées cliniques positives de Tedopi®, son vaccin thérapeutique contre le cancer en développement avancé

OSE Immunotherapeutics annonce des avancées cliniques positives de Tedopi®, son vaccin thérapeutique contre le cancer en développement avancé OSE Immunotherapeutics annonce des avancées cliniques...

OSE Immunotherapeutics : Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital

OSE Immunotherapeutics : Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant...

OSE Immunotherapeutics Renforce son Équipe de Direction et son Comité Exécutif

OSE Immunotherapeutics Renforce son Équipe de Direction et son Comité Exécutif OSE Immunotherapeutics Renforce son Équipe de Direction et son Comité Exécutif Nantes, France, le 2 décembre 2024...

OSE Immunotherapeutics Strengthens Leadership and Executive Committee

OSE Immunotherapeutics Strengthens Leadership and Executive Committee OSE Immunotherapeutics Strengthens Leadership and Executive Committee NANTES, France, December 2, 2024 – 6:00pm CET - OSE...

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 4 novembre 2024 – En application de l’article L. 233-8 II du Code de commerce et de l’article...

OSE Immunotherapeutics Annonce des Résultats Cliniquement Probants et Statistiquement Significatifs de l’Étude de Phase 2 de l’Anticorps Anti-IL7R Lusvertikimab pour le Traitement de la Rectocolite Hémorragique

OSE Immunotherapeutics Annonce des Résultats Cliniquement Probants et Statistiquement Significatifs de l’Étude de Phase 2 de l’Anticorps Anti-IL7R Lusvertikimab pour le Traitement de la...

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis OSE...

Period	Open	High	Low	Avg. Daily Vol	VWAP
1	4.12	4.12	4.12	154	4.12	DE
4	4.12	4.12	4.12	118	4.12	DE
12	4.12	4.12	4.12	138	4.12	DE
26	4.12	4.12	4.12	125	4.12	DE
52	4.12	4.12	4.12	403	4.12	DE
156	4.12	4.12	4.12	761	4.12	DE
260	4.12	4.12	4.12	886	4.12	DE

0RAD - Frequently Asked Questions (FAQ)

What is the current Ose Immunotherapeutics share price?

The current share price of Ose Immunotherapeutics is 4.12 €

How many Ose Immunotherapeutics shares are in issue?

Ose Immunotherapeutics has 21,651,000 shares in issue

What is the market cap of Ose Immunotherapeutics?

The market capitalisation of Ose Immunotherapeutics is EUR 89.2M

What is the 1 year trading range for Ose Immunotherapeutics share price?

Ose Immunotherapeutics has traded in the range of 4.12 € to 4.12 € during the past year

What is the PE ratio of Ose Immunotherapeutics?

The price to earnings ratio of Ose Immunotherapeutics is -7.12

What is the cash to sales ratio of Ose Immunotherapeutics?

The cash to sales ratio of Ose Immunotherapeutics is 73.47

What is the reporting currency for Ose Immunotherapeutics?

Ose Immunotherapeutics reports financial results in EUR

What is the latest annual turnover for Ose Immunotherapeutics?

The latest annual turnover of Ose Immunotherapeutics is EUR 2.23M

What is the latest annual profit for Ose Immunotherapeutics?

The latest annual profit of Ose Immunotherapeutics is EUR -23M

What is the registered address of Ose Immunotherapeutics?

The registered address for Ose Immunotherapeutics is 22 BOULEVARD DE BENONI GOULLIN, NANTES, LOIRE-ATLANTIQUE, 44200

What is the Ose Immunotherapeutics website address?

The website address for Ose Immunotherapeutics is www.ose-immuno.com

Which industry sector does Ose Immunotherapeutics operate in?

Ose Immunotherapeutics operates in the COML PHYSICAL, BIOLOGCL RESH sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TCFTheracryf Plc	0.725p (38.10%)	7.56M
NMTNeometals Ltd	3.50p (27.27%)	346.81k
SCHOScholium Group Plc	44.00p (25.71%)	30.65k
FABFusion Antibodies Plc	10.15p (24.54%)	3.34M
PYXPyx Resources Limited	3.49p (22.24%)	8.43k
TM1Technology Minerals Plc	0.125p (-24.24%)	37.21M
QUIZQuiz Plc	0.70p (-18.60%)	3.67M
SYMESupply@me Capital Plc	0.003p (-17.81%)	168.35M
OBDOxford Biodynamics Plc	1.20p (-14.29%)	827.83k
ZENZenith Energy Ltd.	5.25p (-13.93%)	5.39M
TRPTower Resources Plc	0.0395p (5.33%)	539.51M
CPXCap-xx Limited	0.1825p (1.39%)	494M
NTVONativo Resources Plc	0.0019p (0.00%)	320.16M
DGIDg Innovate Plc	0.0225p (-13.46%)	208.21M
ENETEthernity Networks Ltd	0.1125p (2.27%)	207.56M